Literature DB >> 6180990

Direct cytolysis by partially-purified preparations of immune interferon.

S Tyring, G R Klimpel, W R Fleischmann, S Baron.   

Abstract

Mouse IFN gamma preparations purified 30-fold were found to have direct cytolytic activity against a number of tumor and normal cells. Cell killing was determined using a sensitive, rapid and accurate assay which employed very low numbers of cells and very small quantities of interferon. The cytolytic activity of IFN gamma on 11 murine tumor cell lines was investigated. A 20-fold difference was found between the most-sensitive cell type, P-388 lymphoma, versus the most resistant cell type, C127v leukemia. A number of normal mouse cells was also found to have low to intermediate sensitivity to the cytolytic action of IFN gamma. Human IFN gamma was also shown to have cytolytic activity which, like mouse IFN gamma, was relatively species-specific. Direct cytolysis was not found to be a characteristic of IFN-alpha/beta. Different mechanisms of action for the antiviral and cytolytic activities of IFN gamma are indicated because the cytolytic titer of IFN gamma did not parallel its antiviral titer on most cell types and increasing the cell number produced a decrease in the cytolytic titer and an increase in the anti-viral titer. High concentrations of IFN gamma (i.e., 2,900 units/ml) resulted in complete lysis of cells within 24 h, while lower concentrations (i.e., 700 units/ml) resulted in a reversible inhibition of cell growth during this time period. Evidence that the cytolytic substance in the IFN gamma preparation was IFN gamma include the following: (1) both antiviral and anticellular activities copurified through a 30-fold purification; and both activities were (2) relatively species-specific; (3) sensitive to heat; (4) inactivated by low pH and (5) neutralized by antibodies to IFN gamma. Therefore, we propose the possibility that direct cytolysis is yet another of IFN gamma's distinctive antivities.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6180990     DOI: 10.1002/ijc.2910300111

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Lysing of fresh human tumor by a cytotoxic factor derived from autologous large granular lymphocytes independently of other known cytokines.

Authors:  A Uchida; T Fujimoto; Y Mizutani
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Correlation of the therapeutic effect of activated tumor-draining lymph node cells with specific interferon-gamma production in vitro.

Authors:  S Sameshima; K Sakai; H Nagawa; N Tsuno; J Kitayama; T Muto
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

4.  Immunological memory induced by genetically transduced tumor cells.

Authors:  M M Dar; Z Abdel-Wahab; C E Vervaert; T Darrow; J Barber; H F Seigler
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

Review 5.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  Identity of human B-cell line cytotoxic lymphokine with tumor necrosis factor type beta.

Authors:  H I Yamanaka; A Karpas
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts.

Authors:  S L Gupta; J M Carlin; P Pyati; W Dai; E R Pfefferkorn; M J Murphy
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  Effect of mouse lymphokines and cloned mouse interferon-gamma on the interaction of Rickettsia prowazekii with mouse macrophage-like RAW264.7 cells.

Authors:  J Turco; H H Winkler
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

9.  Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects.

Authors:  T Yamasaki; H Handa; J Yamashita; Y Watanabe; Y Namba; M Hanaoka
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

10.  Human chromosomes 6 and 21 are required for sensitivity to human interferon gamma.

Authors:  V Jung; A Rashidbaigi; C Jones; J A Tischfield; T B Shows; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.